Clinical Trial Update: A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update comparing oral asciminib with other tyrosine kinase inhibitors in adults with newly diagnosed Philadelphia chromosome-positive chr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Asciminib (asciminib)
• Bosutinib (bosutinib)
• DASATINIB (Dasatinib)
• Imatinib (imatinib)
• Nilotinib (nilotinib)
• Ponatinib (ponatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-03-10